{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T13:05:43Z","timestamp":1792069543100,"version":"4.4.0"},"reference-count":282,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T00:00:00Z","timestamp":1775260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Epigenet"],"DOI":"10.1186\/s13148-026-02112-1","type":"journal-article","created":{"date-parts":[[2026,4,4]],"date-time":"2026-04-04T09:57:11Z","timestamp":1775296631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Unveiling the epigenetic landscape: transforming renal cell carcinoma treatment"],"prefix":"10.1186","volume":"18","author":[{"given":"Fengyu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haifeng","family":"Ni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meiqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shenghao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongyu","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,4]]},"reference":[{"issue":"1","key":"2112_CR1","first-page":"7","volume":"69","author":"RL Siegel","year":"2019","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7\u201334.","journal-title":"CA Cancer J Clin"},{"issue":"3","key":"2112_CR2","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2024;74(3):229\u201363.","journal-title":"CA Cancer J Clin"},{"issue":"5","key":"2112_CR3","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1016\/j.eururo.2022.06.016","volume":"82","author":"H Moch","year":"2022","unstructured":"Moch H, et al. The 2022 World Health Organization classification of tumours of the urinary system and male genital organs-Part A: renal, penile, and testicular tumours. Eur Urol. 2022;82(5):458\u201368.","journal-title":"Eur Urol"},{"issue":"12","key":"2112_CR4","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1001\/jama.2024.12848","volume":"332","author":"TL Rose","year":"2024","unstructured":"Rose TL, Kim WY. Renal cell carcinoma: a review. JAMA. 2024;332(12):1001\u201310.","journal-title":"JAMA"},{"issue":"5","key":"2112_CR5","volume":"5","author":"F Kunath","year":"2017","unstructured":"Kunath F, et al. Partial nephrectomy versus radical nephrectomy for clinical localised renal masses. Cochrane Database Syst Rev. 2017;5(5):Cd012045.","journal-title":"Cochrane Database Syst Rev"},{"issue":"12","key":"2112_CR6","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1007\/s12032-018-1217-1","volume":"35","author":"P Wiechno","year":"2018","unstructured":"Wiechno P, et al. Contemporary treatment of metastatic renal cell carcinoma. Med Oncol. 2018;35(12):156.","journal-title":"Med Oncol"},{"issue":"4","key":"2112_CR7","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s40291-018-0337-9","volume":"22","author":"BN Lasseigne","year":"2018","unstructured":"Lasseigne BN, Brooks JD. The role of DNA methylation in renal cell carcinoma. Mol Diagn Ther. 2018;22(4):431\u201342.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"2112_CR8","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s12672-023-00843-8","volume":"14","author":"X Zhou","year":"2023","unstructured":"Zhou X, et al. The role of RNA modification in urological cancers: mechanisms and clinical potential. Discov Oncol. 2023;14(1):235.","journal-title":"Discov Oncol"},{"issue":"6","key":"2112_CR9","doi-asserted-by":"publisher","first-page":"2655","DOI":"10.1016\/j.juro.2007.07.116","volume":"178","author":"F Christoph","year":"2007","unstructured":"Christoph F, et al. mRNA expression profiles of methylated APAF-1 and DAPK-1 tumor suppressor genes uncover clear cell renal cell carcinomas with aggressive phenotype. J Urol. 2007;178(6):2655\u20139.","journal-title":"J Urol"},{"issue":"12","key":"2112_CR10","doi-asserted-by":"publisher","first-page":"2384","DOI":"10.1002\/1878-0261.13204","volume":"16","author":"JC van der Mijn","year":"2022","unstructured":"van der Mijn JC, et al. The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Mol Oncol. 2022;16(12):2384\u201395.","journal-title":"Mol Oncol"},{"key":"2112_CR11","doi-asserted-by":"publisher","first-page":"1103471","DOI":"10.3389\/fcimb.2023.1103471","volume":"13","author":"X Teng","year":"2023","unstructured":"Teng X, et al. Identification of hub genes and pathways of ferroptosis in fusarium keratitis by bioinformatics methods. Front Cell Infect Microbiol. 2023;13:1103471.","journal-title":"Front Cell Infect Microbiol"},{"issue":"5","key":"2112_CR12","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1016\/j.eururo.2005.11.035","volume":"49","author":"A Lopez-Beltran","year":"2006","unstructured":"Lopez-Beltran A, et al. 2004 WHO classification of the renal tumors of the adults. Eur Urol. 2006;49(5):798\u2013805.","journal-title":"Eur Urol"},{"issue":"3","key":"2112_CR13","doi-asserted-by":"publisher","first-page":"224","DOI":"10.1159\/000538106","volume":"10","author":"Z Han","year":"2024","unstructured":"Han Z, et al. A deep insight into ferroptosis in renal disease: facts and perspectives. Kidney Dis (Basel). 2024;10(3):224\u201336.","journal-title":"Kidney Dis (Basel)"},{"issue":"24","key":"2112_CR14","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2004.05.061","volume":"22","author":"WY Kim","year":"2004","unstructured":"Kim WY, Kaelin WG. Role of VHL gene mutation in human cancer. J Clin Oncol. 2004;22(24):4991\u20135004.","journal-title":"J Clin Oncol"},{"key":"2112_CR15","doi-asserted-by":"crossref","unstructured":"Kaelin WG, Jr, Von Hippel-Lindau disease: insights into oxygen sensing, protein degradation, and cancer. J Clin Invest, 2022. 132(18).","DOI":"10.1172\/JCI162480"},{"issue":"1","key":"2112_CR16","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1172\/JCI134813","volume":"130","author":"J Moslehi","year":"2020","unstructured":"Moslehi J, Rathmell WK. The 2019 Nobel Prize honors fundamental discoveries in hypoxia response. J Clin Invest. 2020;130(1):4\u20136.","journal-title":"J Clin Invest"},{"issue":"40","key":"2112_CR17","doi-asserted-by":"publisher","first-page":"6656","DOI":"10.2174\/0109298673255656231003111621","volume":"31","author":"B Hu","year":"2024","unstructured":"Hu B, et al. Research progress of pyroptosis in renal diseases. Curr Med Chem. 2024;31(40):6656\u201371.","journal-title":"Curr Med Chem"},{"key":"2112_CR18","doi-asserted-by":"publisher","first-page":"1615681","DOI":"10.3389\/fphar.2025.1615681","volume":"16","author":"M Zhang","year":"2025","unstructured":"Zhang M, et al. Renal aging and its consequences: navigating the challenges of an aging population. Front Pharmacol. 2025;16:1615681.","journal-title":"Front Pharmacol"},{"issue":"2","key":"2112_CR19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.eururo.2024.10.019","volume":"87","author":"R Barragan-Carrillo","year":"2025","unstructured":"Barragan-Carrillo R, et al. First and second-line treatments in metastatic renal cell carcinoma. Eur Urol. 2025;87(2):143\u201354.","journal-title":"Eur Urol"},{"issue":"12","key":"2112_CR20","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1007\/s00345-018-2288-5","volume":"36","author":"ER Maher","year":"2018","unstructured":"Maher ER. Hereditary renal cell carcinoma syndromes: diagnosis, surveillance and management. World J Urol. 2018;36(12):1891\u20138.","journal-title":"World J Urol"},{"issue":"6","key":"2112_CR21","doi-asserted-by":"publisher","first-page":"754","DOI":"10.1016\/j.eururo.2019.06.015","volume":"76","author":"MI Carlo","year":"2019","unstructured":"Carlo MI, et al. Familial kidney cancer: implications of new syndromes and molecular insights. Eur Urol. 2019;76(6):754\u201364.","journal-title":"Eur Urol"},{"issue":"6","key":"2112_CR22","doi-asserted-by":"publisher","first-page":"2376","DOI":"10.1021\/cr500491u","volume":"115","author":"H Huang","year":"2015","unstructured":"Huang H, et al. Quantitative proteomic analysis of histone modifications. Chem Rev. 2015;115(6):2376\u2013418.","journal-title":"Chem Rev"},{"issue":"4","key":"2112_CR23","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1038\/s41581-018-0103-6","volume":"15","author":"C Guo","year":"2019","unstructured":"Guo C, et al. Epigenetic regulation in AKI and kidney repair: mechanisms and therapeutic implications. Nat Rev Nephrol. 2019;15(4):220\u201339.","journal-title":"Nat Rev Nephrol"},{"key":"2112_CR24","unstructured":"Jenuwein TA, CD, Translating the histone code. Science (New York, N.Y.), 2001\u201308\u201310."},{"issue":"3","key":"2112_CR25","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/cr.2011.22","volume":"21","author":"AJ Bannister","year":"2011","unstructured":"Bannister AJ, Kouzarides T. Regulation of chromatin by histone modifications. Cell Res. 2011;21(3):381\u201395.","journal-title":"Cell Res"},{"issue":"1","key":"2112_CR26","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.jmb.2011.01.040","volume":"409","author":"KE Gardner","year":"2011","unstructured":"Gardner KE, Allis CD, Strahl BD. Operating on chromatin, a colorful language where context matters. J Mol Biol. 2011;409(1):36\u201346.","journal-title":"J Mol Biol"},{"issue":"6","key":"2112_CR27","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41581-019-0135-6","volume":"15","author":"M Kato","year":"2019","unstructured":"Kato M, Natarajan R. Epigenetics and epigenomics in diabetic kidney disease and metabolic memory. Nat Rev Nephrol. 2019;15(6):327\u201345.","journal-title":"Nat Rev Nephrol"},{"issue":"2","key":"2112_CR28","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1038\/nrn3427","volume":"14","author":"J Gr\u00e4ff","year":"2013","unstructured":"Gr\u00e4ff J, Tsai L-H. Histone acetylation: molecular mnemonics on the chromatin. Nat Rev Neurosci. 2013;14(2):97\u2013111.","journal-title":"Nat Rev Neurosci"},{"issue":"37","key":"2112_CR29","doi-asserted-by":"publisher","first-page":"5319","DOI":"10.1038\/sj.onc.1210602","volume":"26","author":"MR Parthun","year":"2007","unstructured":"Parthun MR. Hat1: the emerging cellular roles of a type B histone acetyltransferase. Oncogene. 2007;26(37):5319\u201328.","journal-title":"Oncogene"},{"issue":"6","key":"2112_CR30","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.sbi.2008.11.004","volume":"18","author":"CE Berndsen","year":"2008","unstructured":"Berndsen CE, Denu JM. Catalysis and substrate selection by histone\/protein lysine acetyltransferases. Curr Opin Struct Biol. 2008;18(6):682\u20139.","journal-title":"Curr Opin Struct Biol"},{"issue":"1","key":"2112_CR31","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/nrg2485","volume":"10","author":"M Haberland","year":"2009","unstructured":"Haberland M, Montgomery RL, Olson EN. The many roles of histone deacetylases in development and physiology: implications for disease and therapy. Nat Rev Genet. 2009;10(1):32\u201342.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2112_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.3390\/pathophysiology29030038","volume":"29","author":"S Kulthinee","year":"2022","unstructured":"Kulthinee S, et al. Critical functions of histone deacetylases (HDACs) in modulating inflammation associated with cardiovascular diseases. Pathophysiology. 2022;29(3):471\u201385.","journal-title":"Pathophysiology"},{"key":"2112_CR33","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1016\/j.mrrev.2017.09.003","volume":"780","author":"F Gong","year":"2019","unstructured":"Gong F, Miller KM. Histone methylation and the DNA damage response. Mutat Res Rev Mutat Res. 2019;780:37\u201347.","journal-title":"Mutat Res Rev Mutat Res"},{"issue":"4","key":"2112_CR34","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1016\/j.molcel.2012.11.006","volume":"48","author":"JC Black","year":"2012","unstructured":"Black JC, Van Rechem C, Whetstine JR. Histone lysine methylation dynamics: establishment, regulation, and biological impact. Mol Cell. 2012;48(4):491\u2013507.","journal-title":"Mol Cell"},{"key":"2112_CR35","doi-asserted-by":"publisher","DOI":"10.1016\/j.sbi.2023.102707","volume":"83","author":"L Sarah","year":"2023","unstructured":"Sarah L, Fujimori DG. Recent developments in catalysis and inhibition of the Jumonji histone demethylases. Curr Opin Struct Biol. 2023;83:102707.","journal-title":"Curr Opin Struct Biol"},{"issue":"6683","key":"2112_CR36","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1038\/30764","volume":"393","author":"X Nan","year":"1998","unstructured":"Nan X, et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature. 1998;393(6683):386\u20139.","journal-title":"Nature"},{"key":"2112_CR37","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1146\/annurev.biochem.74.010904.153721","volume":"74","author":"MG Goll","year":"2005","unstructured":"Goll MG, Bestor TH. Eukaryotic cytosine methyltransferases. Annu Rev Biochem. 2005;74:481\u2013514.","journal-title":"Annu Rev Biochem"},{"issue":"6337","key":"2112_CR38","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1126\/science.aag3260","volume":"356","author":"Y Takahashi","year":"2017","unstructured":"Takahashi Y, et al. Integration of CpG-free DNA induces de novo methylation of CpG islands in pluripotent stem cells. Science. 2017;356(6337):503\u20138.","journal-title":"Science"},{"issue":"6453","key":"2112_CR39","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1038\/366362a0","volume":"366","author":"E Li","year":"1993","unstructured":"Li E, Beard C, Jaenisch R. Role for DNA methylation in genomic imprinting. Nature. 1993;366(6453):362\u20135.","journal-title":"Nature"},{"issue":"10","key":"2112_CR40","doi-asserted-by":"publisher","first-page":"1057","DOI":"10.1038\/nbt.1685","volume":"28","author":"A Portela","year":"2010","unstructured":"Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28(10):1057\u201368.","journal-title":"Nat Biotechnol"},{"issue":"6","key":"2112_CR41","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1016\/0092-8674(92)90611-F","volume":"69","author":"E Li","year":"1992","unstructured":"Li E, Bestor TH, Jaenisch R. Targeted mutation of the DNA methyltransferase gene results in embryonic lethality. Cell. 1992;69(6):915\u201326.","journal-title":"Cell"},{"issue":"5","key":"2112_CR42","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a019133","volume":"6","author":"E Li","year":"2014","unstructured":"Li E, Zhang Y. DNA methylation in mammals. Cold Spring Harb Perspect Biol. 2014;6(5):a019133.","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"2112_CR43","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1146\/annurev-biochem-103019-102815","volume":"89","author":"Z Chen","year":"2020","unstructured":"Chen Z, Zhang Y. Role of mammalian DNA methyltransferases in development. Annu Rev Biochem. 2020;89:135\u201358.","journal-title":"Annu Rev Biochem"},{"issue":"2","key":"2112_CR44","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/nrg.2017.80","volume":"19","author":"F Lyko","year":"2018","unstructured":"Lyko F. The DNA methyltransferase family: a versatile toolkit for epigenetic regulation. Nat Rev Genet. 2018;19(2):81\u201392.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2112_CR45","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1038\/s41392-023-01537-x","volume":"8","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. TET (Ten-eleven translocation) family proteins: structure, biological functions and applications. Signal Transduct Target Ther. 2023;8(1):297.","journal-title":"Signal Transduct Target Ther"},{"issue":"2","key":"2112_CR46","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1038\/s43018-021-00316-3","volume":"3","author":"Y Xie","year":"2022","unstructured":"Xie Y, et al. SETD2 loss perturbs the kidney cancer epigenetic landscape to promote metastasis and engenders actionable dependencies on histone chaperone complexes. Nat Cancer. 2022;3(2):188\u2013202.","journal-title":"Nat Cancer"},{"key":"2112_CR47","doi-asserted-by":"publisher","first-page":"1247690","DOI":"10.3389\/fmed.2023.1247690","volume":"10","author":"L You","year":"2023","unstructured":"You L, et al. The role of N6-methyladenosine (m(6)A) in kidney diseases. Front Med (Lausanne). 2023;10:1247690.","journal-title":"Front Med (Lausanne)"},{"issue":"12","key":"2112_CR48","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1038\/nchembio.687","volume":"7","author":"G Jia","year":"2011","unstructured":"Jia G, et al. N6-methyladenosine in nuclear RNA is a major substrate of the obesity-associated FTO. Nat Chem Biol. 2011;7(12):885\u20137.","journal-title":"Nat Chem Biol"},{"issue":"1","key":"2112_CR49","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.molcel.2012.10.015","volume":"49","author":"G Zheng","year":"2013","unstructured":"Zheng G, et al. ALKBH5 is a mammalian RNA demethylase that impacts RNA metabolism and mouse fertility. Mol Cell. 2013;49(1):18\u201329.","journal-title":"Mol Cell"},{"issue":"11","key":"2112_CR50","first-page":"1233","volume":"3","author":"JA Bokar","year":"1997","unstructured":"Bokar JA, et al. Purification and cDNA cloning of the AdoMet-binding subunit of the human mRNA (N6-adenosine)-methyltransferase. RNA. 1997;3(11):1233\u201347.","journal-title":"RNA"},{"issue":"7397","key":"2112_CR51","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/nature11112","volume":"485","author":"D Dominissini","year":"2012","unstructured":"Dominissini D, et al. Topology of the human and mouse m6A RNA methylomes revealed by m6A-seq. Nature. 2012;485(7397):201\u20136.","journal-title":"Nature"},{"issue":"1","key":"2112_CR52","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1038\/s41420-024-02092-2","volume":"10","author":"X Han","year":"2024","unstructured":"Han X, et al. Progression of m(6)A in the tumor microenvironment: hypoxia, immune and metabolic reprogramming. Cell Death Discov. 2024;10(1):331.","journal-title":"Cell Death Discov"},{"issue":"10","key":"2112_CR53","doi-asserted-by":"publisher","first-page":"3971","DOI":"10.1073\/pnas.71.10.3971","volume":"71","author":"R Desrosiers","year":"1974","unstructured":"Desrosiers R, Friderici K, Rottman F. Identification of methylated nucleosides in messenger RNA from Novikoff hepatoma cells. Proc Natl Acad Sci U S A. 1974;71(10):3971\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"2112_CR54","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1038\/nrg3724","volume":"15","author":"Y Fu","year":"2014","unstructured":"Fu Y, et al. Gene expression regulation mediated through reversible m\u2076A RNA methylation. Nat Rev Genet. 2014;15(5):293\u2013306.","journal-title":"Nat Rev Genet"},{"issue":"1","key":"2112_CR55","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s12943-019-1033-z","volume":"18","author":"XY Chen","year":"2019","unstructured":"Chen XY, Zhang J, Zhu JS. The role of m(6)A RNA methylation in human cancer. Mol Cancer. 2019;18(1):103.","journal-title":"Mol Cancer"},{"issue":"8","key":"2112_CR56","doi-asserted-by":"publisher","first-page":"1672","DOI":"10.1021\/bi00627a023","volume":"16","author":"CM Wei","year":"1977","unstructured":"Wei CM, Moss B. Nucleotide sequences at the N6-methyladenosine sites of HeLa cell messenger ribonucleic acid. Biochemistry. 1977;16(8):1672\u20136.","journal-title":"Biochemistry"},{"issue":"2","key":"2112_CR57","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/nchembio.1432","volume":"10","author":"J Liu","year":"2014","unstructured":"Liu J, et al. A METTL3-METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation. Nat Chem Biol. 2014;10(2):93\u20135.","journal-title":"Nat Chem Biol"},{"issue":"2","key":"2112_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1038\/cr.2014.3","volume":"24","author":"XL Ping","year":"2014","unstructured":"Ping XL, et al. Mammalian WTAP is a regulatory subunit of the RNA N6-methyladenosine methyltransferase. Cell Res. 2014;24(2):177\u201389.","journal-title":"Cell Res"},{"key":"2112_CR59","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41421-018-0019-0","volume":"4","author":"Y Yue","year":"2018","unstructured":"Yue Y, et al. VIRMA mediates preferential m(6)A mRNA methylation in 3\u2019UTR and near stop codon and associates with alternative polyadenylation. Cell Discov. 2018;4:10.","journal-title":"Cell Discov"},{"issue":"7620","key":"2112_CR60","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1038\/nature19342","volume":"537","author":"DP Patil","year":"2016","unstructured":"Patil DP, et al. m(6)A RNA methylation promotes XIST-mediated transcriptional repression. Nature. 2016;537(7620):369\u201373.","journal-title":"Nature"},{"issue":"6","key":"2112_CR61","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1016\/j.molcel.2018.02.015","volume":"69","author":"J Wen","year":"2018","unstructured":"Wen J, et al. Zc3h13 regulates nuclear RNA m(6)A methylation and mouse embryonic stem cell self-renewal. Mol Cell. 2018;69(6):1028-1038.e6.","journal-title":"Mol Cell"},{"issue":"45","key":"2112_CR62","doi-asserted-by":"publisher","first-page":"13475","DOI":"10.1021\/bi00249a036","volume":"33","author":"A Bakin","year":"1994","unstructured":"Bakin A, Lane BG, Ofengand J. Clustering of pseudouridine residues around the peptidyltransferase center of yeast cytoplasmic and mitochondrial ribosomes. Biochemistry. 1994;33(45):13475\u201383.","journal-title":"Biochemistry"},{"issue":"5","key":"2112_CR63","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1016\/j.cell.2017.05.003","volume":"169","author":"KE Pendleton","year":"2017","unstructured":"Pendleton KE, et al. The U6 snRNA m(6)A methyltransferase METTL16 regulates SAM synthetase intron retention. Cell. 2017;169(5):824-835.e14.","journal-title":"Cell"},{"issue":"34","key":"2112_CR64","doi-asserted-by":"publisher","first-page":"20734","DOI":"10.1074\/jbc.R115.656462","volume":"290","author":"BI Fedeles","year":"2015","unstructured":"Fedeles BI, et al. The AlkB family of Fe(II)\/\u03b1-Ketoglutarate-dependent dioxygenases: repairing nucleic acid alkylation damage and beyond. J Biol Chem. 2015;290(34):20734\u201342.","journal-title":"J Biol Chem"},{"issue":"6","key":"2112_CR65","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.molcel.2018.08.011","volume":"71","author":"J Wei","year":"2018","unstructured":"Wei J, et al. Differential m(6)A, m(6)A(m), and m(1)A demethylation mediated by FTO in the cell nucleus and cytoplasm. Mol Cell. 2018;71(6):973-985.e5.","journal-title":"Mol Cell"},{"issue":"6","key":"2112_CR66","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.cell.2015.05.014","volume":"161","author":"X Wang","year":"2015","unstructured":"Wang X, et al. N(6)-methyladenosine modulates messenger RNA translation efficiency. Cell. 2015;161(6):1388\u201399.","journal-title":"Cell"},{"issue":"7481","key":"2112_CR67","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1038\/nature12730","volume":"505","author":"X Wang","year":"2014","unstructured":"Wang X, et al. N6-methyladenosine-dependent regulation of messenger RNA stability. Nature. 2014;505(7481):117\u201320.","journal-title":"Nature"},{"issue":"3","key":"2112_CR68","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/cr.2017.15","volume":"27","author":"H Shi","year":"2017","unstructured":"Shi H, et al. YTHDF3 facilitates translation and decay of N(6)-methyladenosine-modified RNA. Cell Res. 2017;27(3):315\u201328.","journal-title":"Cell Res"},{"issue":"3","key":"2112_CR69","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/s41556-018-0045-z","volume":"20","author":"H Huang","year":"2018","unstructured":"Huang H, et al. Recognition of RNA N(6)-methyladenosine by IGF2BP proteins enhances mRNA stability and translation. Nat Cell Biol. 2018;20(3):285\u201395.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2112_CR70","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1080\/15476286.2018.1564617","volume":"16","author":"U Das","year":"2019","unstructured":"Das U, Nguyen H, Xie J. Transcriptome protection by the expanded family of hnRNPs. RNA Biol. 2019;16(2):155\u20139.","journal-title":"RNA Biol"},{"issue":"5740","key":"2112_CR71","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1126\/science.1112014","volume":"309","author":"P Carninci","year":"2005","unstructured":"Carninci P, et al. The transcriptional landscape of the mammalian genome. Science. 2005;309(5740):1559\u201363.","journal-title":"Science"},{"issue":"7235","key":"2112_CR72","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1038\/nature07672","volume":"458","author":"M Guttman","year":"2009","unstructured":"Guttman M, et al. Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature. 2009;458(7235):223\u20137.","journal-title":"Nature"},{"issue":"2","key":"2112_CR73","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/S0092-8674(04)00045-5","volume":"116","author":"DP Bartel","year":"2004","unstructured":"Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2):281\u201397.","journal-title":"Cell"},{"issue":"3","key":"2112_CR74","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1038\/nrd.2016.246","volume":"16","author":"R Rupaimoole","year":"2017","unstructured":"Rupaimoole R, Slack FJ. MicroRNA therapeutics: towards a new era for the management of cancer and other diseases. Nat Rev Drug Discov. 2017;16(3):203\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"2112_CR75","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2022.932693","volume":"13","author":"C Liu","year":"2022","unstructured":"Liu C, et al. Kidney diseases and long non-coding RNAs in the limelight. Front Physiol. 2022;13:932693.","journal-title":"Front Physiol"},{"issue":"7014","key":"2112_CR76","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1038\/nature03049","volume":"432","author":"AM Denli","year":"2004","unstructured":"Denli AM, et al. Processing of primary microRNAs by the microprocessor complex. Nature. 2004;432(7014):231\u20135.","journal-title":"Nature"},{"issue":"7014","key":"2112_CR77","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1038\/nature03120","volume":"432","author":"RI Gregory","year":"2004","unstructured":"Gregory RI, et al. The Microprocessor complex mediates the genesis of microRNAs. Nature. 2004;432(7014):235\u201340.","journal-title":"Nature"},{"issue":"24","key":"2112_CR78","doi-asserted-by":"publisher","first-page":"3016","DOI":"10.1101\/gad.1262504","volume":"18","author":"J Han","year":"2004","unstructured":"Han J, et al. The Drosha-DGCR8 complex in primary microRNA processing. Genes Dev. 2004;18(24):3016\u201327.","journal-title":"Genes Dev"},{"issue":"6956","key":"2112_CR79","doi-asserted-by":"publisher","first-page":"415","DOI":"10.1038\/nature01957","volume":"425","author":"Y Lee","year":"2003","unstructured":"Lee Y, et al. The nuclear RNase III drosha initiates microRNA processing. Nature. 2003;425(6956):415\u20139.","journal-title":"Nature"},{"issue":"2","key":"2112_CR80","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1261\/rna.5167604","volume":"10","author":"MT Bohnsack","year":"2004","unstructured":"Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA. 2004;10(2):185\u201391.","journal-title":"RNA"},{"issue":"5654","key":"2112_CR81","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1126\/science.1090599","volume":"303","author":"E Lund","year":"2004","unstructured":"Lund E, et al. Nuclear export of microRNA precursors. Science. 2004;303(5654):95\u20138.","journal-title":"Science"},{"issue":"1","key":"2112_CR82","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/S0092-8674(04)00261-2","volume":"117","author":"YS Lee","year":"2004","unstructured":"Lee YS, et al. Distinct roles for drosophila dicer-1 and Dicer-2 in the siRNA\/miRNA silencing pathways. Cell. 2004;117(1):69\u201381.","journal-title":"Cell"},{"issue":"4","key":"2112_CR83","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.cell.2005.10.022","volume":"123","author":"RI Gregory","year":"2005","unstructured":"Gregory RI, et al. Human RISC couples microRNA biogenesis and posttranscriptional gene silencing. Cell. 2005;123(4):631\u201340.","journal-title":"Cell"},{"key":"2112_CR84","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines11092358","author":"A Gluba-Sagr","year":"2023","unstructured":"Gluba-Sagr A, et al. The role of miRNA in renal fibrosis leading to chronic kidney disease. Biomedicines. 2023. https:\/\/doi.org\/10.3390\/biomedicines11092358.","journal-title":"Biomedicines"},{"issue":"1","key":"2112_CR85","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1038\/s41420-022-01219-7","volume":"8","author":"M Ding","year":"2022","unstructured":"Ding M, et al. Cancer-associated fibroblasts promote the stemness and progression of renal cell carcinoma via exosomal miR-181d-5p. Cell Death Discov. 2022;8(1):439.","journal-title":"Cell Death Discov"},{"issue":"12","key":"2112_CR86","doi-asserted-by":"publisher","first-page":"2252","DOI":"10.1016\/j.molcel.2022.05.027","volume":"82","author":"AB Herman","year":"2022","unstructured":"Herman AB, Tsitsipatis D, Gorospe M. Integrated lncRNA function upon genomic and epigenomic regulation. Mol Cell. 2022;82(12):2252\u201366.","journal-title":"Mol Cell"},{"key":"2112_CR87","doi-asserted-by":"publisher","DOI":"10.1083\/jcb.202009045","author":"MC Bridges","year":"2021","unstructured":"Bridges MC, Daulagala AC, Kourtidis A. LNCcation: lncRNA localization and function. J Cell Biol. 2021. https:\/\/doi.org\/10.1083\/jcb.202009045.","journal-title":"J Cell Biol"},{"issue":"1","key":"2112_CR88","doi-asserted-by":"publisher","first-page":"426","DOI":"10.1038\/s41420-022-01141-y","volume":"8","author":"J Shao","year":"2022","unstructured":"Shao J, et al. Ferrostatin-1 alleviates tissue and cell damage in diabetic retinopathy by improving the antioxidant capacity of the Xc(-)-GPX4 system. Cell Death Discov. 2022;8(1):426.","journal-title":"Cell Death Discov"},{"key":"2112_CR89","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2023.110172","volume":"119","author":"Z Han","year":"2023","unstructured":"Han Z, et al. The role of thyroid hormone in the renal immune microenvironment. Int Immunopharmacol. 2023;119:110172.","journal-title":"Int Immunopharmacol"},{"key":"2112_CR90","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.826732","volume":"13","author":"Z Han","year":"2022","unstructured":"Han Z, et al. A deep insight into regulatory T Cell metabolism in renal disease: facts and perspectives. Front Immunol. 2022;13:826732.","journal-title":"Front Immunol"},{"issue":"5256","key":"2112_CR91","doi-asserted-by":"publisher","first-page":"1734","DOI":"10.1126\/science.271.5256.1734","volume":"271","author":"DR Leach","year":"1996","unstructured":"Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science. 1996;271(5256):1734\u20136.","journal-title":"Science"},{"issue":"11","key":"2112_CR92","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, et al. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. Embo j. 1992;11(11):3887\u201395.","journal-title":"Embo j"},{"issue":"1","key":"2112_CR93","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1186\/s13045-023-01478-6","volume":"16","author":"M Li","year":"2023","unstructured":"Li M, et al. Metabolism, metabolites, and macrophages in cancer. J Hematol Oncol. 2023;16(1):80.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2112_CR94","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1186\/s40001-024-01939-9","volume":"29","author":"J Zhao","year":"2024","unstructured":"Zhao J, et al. Epigenetic modification of PHLDA2 is associated with tumor microenvironment and unfavorable outcome of immune checkpoint inhibitor-based therapies in clear cell renal cell carcinoma. Eur J Med Res. 2024;29(1):378.","journal-title":"Eur J Med Res"},{"issue":"1","key":"2112_CR95","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-023-01771-5","volume":"22","author":"T Li","year":"2023","unstructured":"Li T, et al. CircZBTB44 promotes renal carcinoma progression by stabilizing HK3 mRNA structure. Mol Cancer. 2023;22(1):77.","journal-title":"Mol Cancer"},{"key":"2112_CR96","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-001646","author":"J Zhong","year":"2021","unstructured":"Zhong J, et al. m(6)A modification patterns and tumor immune landscape in clear cell renal carcinoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2020-001646.","journal-title":"J Immunother Cancer"},{"key":"2112_CR97","doi-asserted-by":"publisher","first-page":"1387582","DOI":"10.3389\/fimmu.2024.1387582","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. Exploring the impact of m(6)A modification on immune diseases: mechanisms and therapeutic implication. Front Immunol. 2024;15:1387582.","journal-title":"Front Immunol"},{"issue":"5","key":"2112_CR98","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1038\/nrclinonc.2018.29","volume":"15","author":"D Fukumura","year":"2018","unstructured":"Fukumura D, et al. Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol. 2018;15(5):325\u201340.","journal-title":"Nat Rev Clin Oncol"},{"issue":"36","key":"2112_CR99","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2018.79.2549","volume":"36","author":"JJ Hsieh","year":"2018","unstructured":"Hsieh JJ, et al. Chromosome 3p loss-orchestrated VHL, HIF, and epigenetic deregulation in clear cell renal cell carcinoma. J Clin Oncol. 2018;36(36):Jco2018792549.","journal-title":"J Clin Oncol"},{"issue":"1","key":"2112_CR100","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ccell.2015.12.004","volume":"29","author":"AA Hakimi","year":"2016","unstructured":"Hakimi AA, et al. An integrated metabolic atlas of clear cell renal cell carcinoma. Cancer Cell. 2016;29(1):104\u201316.","journal-title":"Cancer Cell"},{"key":"2112_CR101","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.716462","volume":"9","author":"E Balandeh","year":"2021","unstructured":"Balandeh E, et al. Roles of non-coding RNAs and angiogenesis in glioblastoma. Front Cell Dev Biol. 2021;9:716462.","journal-title":"Front Cell Dev Biol"},{"key":"2112_CR102","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2024.216911","volume":"592","author":"Q Liao","year":"2024","unstructured":"Liao Q, et al. FTO elicits tumor neovascularization in cancer-associated fibroblasts through eliminating m(6)A modifications of multiple pro-angiogenic factors. Cancer Lett. 2024;592:216911.","journal-title":"Cancer Lett"},{"issue":"2","key":"2112_CR103","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/nrm3274","volume":"13","author":"EJ Wagner","year":"2012","unstructured":"Wagner EJ, Carpenter PB. Understanding the language of Lys36 methylation at histone H3. Nat Rev Mol Cell Biol. 2012;13(2):115\u201326.","journal-title":"Nat Rev Mol Cell Biol"},{"issue":"6","key":"2112_CR104","doi-asserted-by":"publisher","first-page":"2006","DOI":"10.1016\/j.celrep.2014.05.026","volume":"7","author":"SX Pfister","year":"2014","unstructured":"Pfister SX, et al. SETD2-dependent histone H3K36 trimethylation is required for homologous recombination repair and genome stability. Cell Rep. 2014;7(6):2006\u201318.","journal-title":"Cell Rep"},{"key":"2112_CR105","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.02482","volume":"3","author":"S Carvalho","year":"2014","unstructured":"Carvalho S, et al. SETD2 is required for DNA double-strand break repair and activation of the p53-mediated checkpoint. Elife. 2014;3:e02482.","journal-title":"Elife"},{"issue":"2","key":"2112_CR106","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/sj.emboj.7601967","volume":"27","author":"JW Edmunds","year":"2008","unstructured":"Edmunds JW, Mahadevan LC, Clayton AL. Dynamic histone H3 methylation during gene induction: HYPB\/Setd2 mediates all H3K36 trimethylation. EMBO J. 2008;27(2):406\u201320.","journal-title":"EMBO J"},{"issue":"12","key":"2112_CR107","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1093\/emboj\/cdg288","volume":"22","author":"GV Rayasam","year":"2003","unstructured":"Rayasam GV. NSD1 is essential for early post-implantation development and has a catalytically active SET domain. EMBO J. 2003;22(12):3153\u201363.","journal-title":"EMBO J"},{"issue":"24","key":"2112_CR108","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1182\/blood-2017-10-811927","volume":"130","author":"JD Licht","year":"2017","unstructured":"Licht JD. SETD2: a complex role in blood malignancy. Blood. 2017;130(24):2576\u20138.","journal-title":"Blood"},{"key":"2112_CR109","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"2112_CR110","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.celrep.2018.03.075","volume":"23","author":"CJ Ricketts","year":"2018","unstructured":"Ricketts CJ, et al. The Cancer genome atlas comprehensive molecular characterization of renal cell carcinoma. Cell Rep. 2018;23(1):313-326.e5.","journal-title":"Cell Rep"},{"issue":"13","key":"2112_CR111","doi-asserted-by":"publisher","first-page":"3554","DOI":"10.1158\/0008-5472.CAN-20-3960","volume":"81","author":"H Rao","year":"2021","unstructured":"Rao H, et al. Multilevel regulation of \u03b2-Catenin activity by SETD2 suppresses the transition from polycystic kidney disease to clear cell renal cell carcinoma. Cancer Res. 2021;81(13):3554\u201367.","journal-title":"Cancer Res"},{"issue":"1","key":"2112_CR112","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1002\/1878-0261.12017","volume":"11","author":"KT Yeung","year":"2017","unstructured":"Yeung KT, Yang J. Epithelial-mesenchymal transition in tumor metastasis. Mol Oncol. 2017;11(1):28\u201339.","journal-title":"Mol Oncol"},{"issue":"1","key":"2112_CR113","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1002\/1878-0261.13487","volume":"18","author":"T Wang","year":"2024","unstructured":"Wang T, et al. SETD2 loss in renal epithelial cells drives epithelial-to-mesenchymal transition in a TGF-\u03b2-independent manner. Mol Oncol. 2024;18(1):44\u201361.","journal-title":"Mol Oncol"},{"issue":"1","key":"2112_CR114","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-023-11162-0","volume":"23","author":"H Javaid","year":"2023","unstructured":"Javaid H, et al. A role for SETD2 loss in tumorigenesis through DNA methylation dysregulation. BMC Cancer. 2023;23(1):721.","journal-title":"BMC Cancer"},{"issue":"25","key":"2112_CR115","doi-asserted-by":"publisher","first-page":"9672","DOI":"10.1021\/acs.analchem.3c01552","volume":"95","author":"J Yin","year":"2023","unstructured":"Yin J, et al. Targeted profiling of epitranscriptomic reader, writer, and eraser proteins regulated by H3K36me3. Anal Chem. 2023;95(25):9672\u20139.","journal-title":"Anal Chem"},{"issue":"5","key":"2112_CR116","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1016\/j.cell.2012.03.042","volume":"149","author":"SJ Dixon","year":"2012","unstructured":"Dixon SJ, et al. Ferroptosis: an iron-dependent form of nonapoptotic cell death. Cell. 2012;149(5):1060\u201372.","journal-title":"Cell"},{"issue":"1-2","key":"2112_CR117","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cell.2013.12.010","volume":"156","author":"WS Yang","year":"2014","unstructured":"Yang WS, et al. Regulation of ferroptotic cancer cell death by GPX4. Cell. 2014;156(1\u20132):317\u201331.","journal-title":"Cell"},{"issue":"4","key":"2112_CR118","doi-asserted-by":"publisher","first-page":"405","DOI":"10.1111\/j.1600-0846.2011.00586.x","volume":"18","author":"AB Petersen","year":"2012","unstructured":"Petersen AB, Philipsen PA, Wulf HC. An explorative study of non-invasive ultra-weak photon emission and the anti-oxidative influence of oral zinc sulphate in light-sensitive patients with erythropoietic protoporphyria. Skin Res Technol. 2012;18(4):405\u201312.","journal-title":"Skin Res Technol"},{"key":"2112_CR119","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.freeradbiomed.2022.06.010","volume":"188","author":"C Yang","year":"2022","unstructured":"Yang C, et al. Flavonoid 4,4\u2019-dimethoxychalcone induced ferroptosis in cancer cells by synergistically activating Keap1\/Nrf2\/HMOX1 pathway and inhibiting FECH. Free Radic Biol Med. 2022;188:14\u201323.","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"2112_CR120","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/s41419-023-06057-8","volume":"14","author":"W Xue","year":"2023","unstructured":"Xue W, et al. Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC. Cell Death Dis. 2023;14(8):539.","journal-title":"Cell Death Dis"},{"issue":"9","key":"2112_CR121","doi-asserted-by":"publisher","first-page":"3621","DOI":"10.7150\/ijbs.70972","volume":"18","author":"J Lin","year":"2022","unstructured":"Lin J, et al. NUF2 drives clear cell renal cell carcinoma by activating HMGA2 transcription through KDM2A-mediated H3K36me2 demethylation. Int J Biol Sci. 2022;18(9):3621\u201335.","journal-title":"Int J Biol Sci"},{"key":"2112_CR122","doi-asserted-by":"publisher","DOI":"10.3390\/genes12020269","author":"B Mansoori","year":"2021","unstructured":"Mansoori B, et al. HMGA2 as a critical regulator in cancer development. Genes (Basel). 2021. https:\/\/doi.org\/10.3390\/genes12020269.","journal-title":"Genes (Basel)"},{"key":"2112_CR123","doi-asserted-by":"crossref","unstructured":"Wang J, et al, Electroacupuncture combined with cisplatin induces an effective anti-tumor immune response by protecting chemotherapy-impaired bone marrow hematopoiesis in non\u2013small cell lung cancer mice. 2025. 5(2): p. 229\u2013245.","DOI":"10.1097\/HM9.0000000000000158"},{"key":"2112_CR124","doi-asserted-by":"crossref","unstructured":"Liu L, et al. Celastrol promotes apoptosis of breast cancer MDA-MB-231 cells by targeting HSDL2. 2024. 4(1): p. 92\u2013101.","DOI":"10.1097\/HM9.0000000000000102"},{"issue":"1","key":"2112_CR125","doi-asserted-by":"publisher","first-page":"4680","DOI":"10.1038\/s41467-022-32472-0","volume":"13","author":"H Cui","year":"2022","unstructured":"Cui H, et al. The SWI\/SNF chromatin remodeling factor DPF3 regulates metastasis of ccRCC by modulating TGF-\u03b2 signaling. Nat Commun. 2022;13(1):4680.","journal-title":"Nat Commun"},{"issue":"13","key":"2112_CR126","doi-asserted-by":"publisher","first-page":"1605","DOI":"10.1101\/gad.14.13.1605","volume":"14","author":"RH Kim","year":"2000","unstructured":"Kim RH, et al. A novel smad nuclear interacting protein, SNIP1, suppresses p300-dependent TGF-beta signal transduction. Genes Dev. 2000;14(13):1605\u201316.","journal-title":"Genes Dev"},{"issue":"6","key":"2112_CR127","doi-asserted-by":"publisher","first-page":"1420","DOI":"10.1172\/JCI39104","volume":"119","author":"R Kalluri","year":"2009","unstructured":"Kalluri R, Weinberg RA. The basics of epithelial-mesenchymal transition. J Clin Invest. 2009;119(6):1420\u20138.","journal-title":"J Clin Invest"},{"key":"2112_CR128","doi-asserted-by":"crossref","unstructured":"Yao L, et al. Acetate promotes SNAI1 expression by ACSS2-mediated histone acetylation under glucose limitation in renal cell carcinoma cell. Biosci Rep, 2020. 40(6).","DOI":"10.1042\/BSR20200382"},{"issue":"38","key":"2112_CR129","doi-asserted-by":"publisher","first-page":"29413","DOI":"10.1074\/jbc.M004645200","volume":"275","author":"T Budiman","year":"2000","unstructured":"Budiman T, et al. Mechanism of electrogenic cation transport by the cloned organic cation transporter 2 from rat. J Biol Chem. 2000;275(38):29413\u201320.","journal-title":"J Biol Chem"},{"issue":"8","key":"2112_CR130","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1080\/15592294.2019.1615354","volume":"14","author":"Q Zhu","year":"2019","unstructured":"Zhu Q, et al. Regulation of OCT2 transcriptional repression by histone acetylation in renal cell carcinoma. Epigenetics. 2019;14(8):791\u2013803.","journal-title":"Epigenetics"},{"issue":"8","key":"2112_CR131","doi-asserted-by":"publisher","first-page":"5050","DOI":"10.4049\/jimmunol.0900259","volume":"183","author":"S Biswas","year":"2009","unstructured":"Biswas S, et al. Elevated levels of select gangliosides in T cells from renal cell carcinoma patients is associated with T cell dysfunction. J Immunol. 2009;183(8):5050\u20138.","journal-title":"J Immunol"},{"issue":"3","key":"2112_CR132","doi-asserted-by":"publisher","first-page":"1005","DOI":"10.1074\/jbc.RA118.004485","volume":"294","author":"A Banerjee","year":"2019","unstructured":"Banerjee A, et al. Elevated histone H3 acetylation and loss of the Sp1-HDAC1 complex de-repress the GM2-synthase gene in renal cell carcinoma. J Biol Chem. 2019;294(3):1005\u201318.","journal-title":"J Biol Chem"},{"issue":"4","key":"2112_CR133","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrclinonc.2018.8","volume":"15","author":"DE Johnson","year":"2018","unstructured":"Johnson DE, O\u2019Keefe RA, Grandis JR. Targeting the IL-6\/JAK\/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234\u201348.","journal-title":"Nat Rev Clin Oncol"},{"key":"2112_CR134","doi-asserted-by":"crossref","unstructured":"Owen KL, Brockwell NK, and Parker BS, JAK-STAT signaling: a double-edged sword of immune regulation and cancer progression. Cancers (Basel), 2019. 11(12).","DOI":"10.3390\/cancers11122002"},{"key":"2112_CR135","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106706","volume":"86","author":"F Liang","year":"2020","unstructured":"Liang F, et al. JAK3 is a potential biomarker and associated with immune infiltration in kidney renal clear cell carcinoma. Int Immunopharmacol. 2020;86:106706.","journal-title":"Int Immunopharmacol"},{"key":"2112_CR136","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1016\/j.jare.2021.11.016","volume":"40","author":"Q Long","year":"2022","unstructured":"Long Q, et al. Prognostic value of JAK3 promoter methylation and mRNA expression in clear cell renal cell carcinoma. J Adv Res. 2022;40:153\u201366.","journal-title":"J Adv Res"},{"key":"2112_CR137","doi-asserted-by":"crossref","unstructured":"Raivola J, et al. Janus Kinases in Leukemia. Cancers (Basel), 2021. 13(4).","DOI":"10.3390\/cancers13040800"},{"issue":"41","key":"2112_CR138","doi-asserted-by":"publisher","first-page":"29439","DOI":"10.1074\/jbc.274.41.29439","volume":"274","author":"P Oettgen","year":"1999","unstructured":"Oettgen P, et al. Characterization of ESE-2, a novel ESE-1-related Ets transcription factor that is restricted to glandular epithelium and differentiated keratinocytes. J Biol Chem. 1999;274(41):29439\u201352.","journal-title":"J Biol Chem"},{"issue":"6","key":"2112_CR139","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1016\/j.tem.2012.02.006","volume":"23","author":"HJ Lee","year":"2012","unstructured":"Lee HJ, Ormandy CJ. Elf5, hormones and cell fate. Trends Endocrinol Metab. 2012;23(6):292\u20138.","journal-title":"Trends Endocrinol Metab"},{"issue":"8","key":"2112_CR140","doi-asserted-by":"publisher","first-page":"872","DOI":"10.1002\/pros.22970","volume":"75","author":"B Yao","year":"2015","unstructured":"Yao B, et al. Elf5 inhibits TGF-\u03b2-driven epithelial-mesenchymal transition in prostate cancer by repressing SMAD3 activation. Prostate. 2015;75(8):872\u201382.","journal-title":"Prostate"},{"issue":"5","key":"2112_CR141","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41556-020-0495-y","volume":"22","author":"S Singh","year":"2020","unstructured":"Singh S, et al. Loss of ELF5-FBXW7 stabilizes IFNGR1 to promote the growth and metastasis of triple-negative breast cancer through interferon-\u03b3 signalling. Nat Cell Biol. 2020;22(5):591\u2013602.","journal-title":"Nat Cell Biol"},{"issue":"2","key":"2112_CR142","doi-asserted-by":"publisher","first-page":"170","DOI":"10.2164\/jandrol.109.008748","volume":"32","author":"BX Xie","year":"2011","unstructured":"Xie BX, et al. Analysis of differentially expressed genes in LNCaP prostate cancer progression model. J Androl. 2011;32(2):170\u201382.","journal-title":"J Androl"},{"issue":"16","key":"2112_CR143","doi-asserted-by":"publisher","first-page":"2671","DOI":"10.1016\/j.febslet.2014.02.041","volume":"588","author":"N Volodko","year":"2014","unstructured":"Volodko N, et al. RASSF tumor suppressor gene family: biological functions and regulation. FEBS Lett. 2014;588(16):2671\u201384.","journal-title":"FEBS Lett"},{"issue":"3","key":"2112_CR144","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/77083","volume":"25","author":"R Dammann","year":"2000","unstructured":"Dammann R, et al. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet. 2000;25(3):315\u20139.","journal-title":"Nat Genet"},{"issue":"1","key":"2112_CR145","doi-asserted-by":"publisher","first-page":"55","DOI":"10.3892\/ijo.2015.3251","volume":"48","author":"J Klacz","year":"2016","unstructured":"Klacz J, et al. Decreased expression of RASSF1A tumor suppressor gene is associated with worse prognosis in clear cell renal cell carcinoma. Int J Oncol. 2016;48(1):55\u201366.","journal-title":"Int J Oncol"},{"issue":"3","key":"2112_CR146","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1111\/iep.12442","volume":"103","author":"YC Lai","year":"2022","unstructured":"Lai YC, et al. Correlations between histological characterizations and methylation statuses of tumour suppressor genes in Wilms\u2019 tumours. Int J Exp Pathol. 2022;103(3):121\u20138.","journal-title":"Int J Exp Pathol"},{"issue":"2","key":"2112_CR147","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.30058","volume":"70","author":"H Ueno-Yokohata","year":"2023","unstructured":"Ueno-Yokohata H, et al. Hypermethylation of RASSF1A gene in pediatric rhabdoid tumor of the kidney and clear cell sarcoma of the kidney. Pediatr Blood Cancer. 2023;70(2):e30058.","journal-title":"Pediatr Blood Cancer"},{"issue":"15","key":"2112_CR148","doi-asserted-by":"publisher","first-page":"3114","DOI":"10.1038\/s41388-020-1195-6","volume":"39","author":"AM Richter","year":"2020","unstructured":"Richter AM, et al. RASSF10 is frequently epigenetically inactivated in kidney cancer and its knockout promotes neoplasia in cancer prone mice. Oncogene. 2020;39(15):3114\u201327.","journal-title":"Oncogene"},{"issue":"1","key":"2112_CR149","doi-asserted-by":"publisher","first-page":"1736793","DOI":"10.1080\/2162402X.2020.1736793","volume":"9","author":"C Wang","year":"2020","unstructured":"Wang C, et al. Integration of intratumoral RASSF10 expression and tumor-associated macrophages into the established clinical indicators better predicts the prognosis of clear cell renal cell carcinoma patients. Oncoimmunology. 2020;9(1):1736793.","journal-title":"Oncoimmunology"},{"issue":"1","key":"2112_CR150","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/nrm.2016.116","volume":"18","author":"B Tian","year":"2017","unstructured":"Tian B, Manley JL. Alternative polyadenylation of mRNA precursors. Nat Rev Mol Cell Biol. 2017;18(1):18\u201330.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2112_CR151","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.162893","author":"Y Tan","year":"2023","unstructured":"Tan Y, et al. Alternative polyadenylation reprogramming of MORC2 induced by NUDT21 loss promotes KIRC carcinogenesis. JCI Insight. 2023. https:\/\/doi.org\/10.1172\/jci.insight.162893.","journal-title":"JCI Insight"},{"key":"2112_CR152","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002949","author":"N Kl\u00fcmper","year":"2021","unstructured":"Kl\u00fcmper N, et al. CTLA4 promoter hypomethylation is a negative prognostic biomarker at initial diagnosis but predicts response and favorable outcome to anti-PD-1 based immunotherapy in clear cell renal cell carcinoma. J Immunother Cancer. 2021. https:\/\/doi.org\/10.1136\/jitc-2021-002949.","journal-title":"J Immunother Cancer"},{"key":"2112_CR153","doi-asserted-by":"publisher","DOI":"10.3390\/ijms242216476","author":"P Faraj Tabrizi","year":"2023","unstructured":"Faraj Tabrizi P, et al. Alteration of cadherin 3 expression and DNA methylation in association with aggressive renal cell carcinoma. Int J Mol Sci. 2023. https:\/\/doi.org\/10.3390\/ijms242216476.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2112_CR154","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/1878-0261.13040","volume":"16","author":"K Miyakuni","year":"2022","unstructured":"Miyakuni K, et al. Genome-wide analysis of DNA methylation identifies the apoptosis-related gene UQCRH as a tumor suppressor in renal cancer. Mol Oncol. 2022;16(3):732\u201349.","journal-title":"Mol Oncol"},{"issue":"10","key":"2112_CR155","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1038\/s41556-018-0201-5","volume":"20","author":"J Doherty","year":"2018","unstructured":"Doherty J, Baehrecke EH. Life, death and autophagy. Nat Cell Biol. 2018;20(10):1110\u20137.","journal-title":"Nat Cell Biol"},{"issue":"15","key":"2112_CR156","doi-asserted-by":"publisher","first-page":"5943","DOI":"10.7150\/ijbs.77774","volume":"18","author":"Y Xu","year":"2022","unstructured":"Xu Y, et al. FTO-mediated autophagy promotes progression of clear cell renal cell carcinoma via regulating SIK2 mRNA stability. Int J Biol Sci. 2022;18(15):5943\u201362.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2112_CR157","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1007\/s00432-023-05541-0","volume":"150","author":"Y He","year":"2024","unstructured":"He Y, et al. The m(6)A demethylase FTO targets POLQ to promote ccRCC cell proliferation and genome stability maintenance. J Cancer Res Clin Oncol. 2024;150(2):30.","journal-title":"J Cancer Res Clin Oncol"},{"issue":"1","key":"2112_CR158","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/s41420-022-01151-w","volume":"8","author":"H Shen","year":"2022","unstructured":"Shen H, et al. FTO promotes clear cell renal cell carcinoma progression via upregulation of PDK1 through an m(6)A dependent pathway. Cell Death Discov. 2022;8(1):356.","journal-title":"Cell Death Discov"},{"issue":"7","key":"2112_CR159","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/s41419-024-06896-z","volume":"15","author":"D Tan","year":"2024","unstructured":"Tan D, et al. N6-methyladenosine-modified ALDH9A1 modulates lipid accumulation and tumor progression in clear cell renal cell carcinoma through the NPM1\/IQGAP2\/AKT signaling pathway. Cell Death Dis. 2024;15(7):520.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2112_CR160","doi-asserted-by":"publisher","DOI":"10.1111\/eci.13986","volume":"53","author":"L Li","year":"2023","unstructured":"Li L, et al. ALKBH1 contributes to renal cell carcinoma progression by reducing N6-methyladenine of GPR137. Eur J Clin Invest. 2023;53(7):e13986.","journal-title":"Eur J Clin Invest"},{"issue":"1","key":"2112_CR161","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1186\/s12967-022-03496-3","volume":"20","author":"D Zhu","year":"2022","unstructured":"Zhu D, et al. The methyltransferase METTL3 promotes tumorigenesis via mediating HHLA2 mRNA m6A modification in human renal cell carcinoma. J Transl Med. 2022;20(1):298.","journal-title":"J Transl Med"},{"key":"2112_CR162","doi-asserted-by":"publisher","first-page":"280","DOI":"10.3389\/fcell.2020.00280","volume":"8","author":"Z Zhang","year":"2020","unstructured":"Zhang Z, et al. Over-expression and prognostic significance of HHLA2, a new immune checkpoint molecule, in human clear cell renal cell carcinoma. Front Cell Dev Biol. 2020;8:280.","journal-title":"Front Cell Dev Biol"},{"key":"2112_CR163","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1186\/s12935-019-0813-2","volume":"19","author":"L Chen","year":"2019","unstructured":"Chen L, et al. Overexpression of HHLA2 in human clear cell renal cell carcinoma is significantly associated with poor survival of the patients. Cancer Cell Int. 2019;19:101.","journal-title":"Cancer Cell Int"},{"key":"2112_CR164","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.737498","volume":"9","author":"Y Shi","year":"2021","unstructured":"Shi Y, et al. The RNA N6-methyladenosine methyltransferase METTL3 promotes the progression of kidney cancer via N6-methyladenosine-dependent translational enhancement of ABCD1. Front Cell Dev Biol. 2021;9:737498.","journal-title":"Front Cell Dev Biol"},{"issue":"1","key":"2112_CR165","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1038\/s41419-023-06411-w","volume":"15","author":"Y Chen","year":"2024","unstructured":"Chen Y, et al. METTL3 facilitates renal cell carcinoma progression by PLOD2 m(6)A-methylation under prolonged hypoxia. Cell Death Dis. 2024;15(1):62.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2112_CR166","doi-asserted-by":"publisher","first-page":"774","DOI":"10.1038\/s41419-023-06298-7","volume":"14","author":"T Liu","year":"2023","unstructured":"Liu T, et al. Hypoxia-induced PLOD2 promotes clear cell renal cell carcinoma progression via modulating EGFR-dependent AKT pathway activation. Cell Death Dis. 2023;14(11):774.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2112_CR167","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.7150\/ijbs.97503","volume":"20","author":"J Tian","year":"2024","unstructured":"Tian J, et al. NOP2-mediated 5-methylcytosine modification of APOL1 messenger RNA activates PI3K-Akt and facilitates clear cell renal cell carcinoma progression. Int J Biol Sci. 2024;20(12):4853\u201371.","journal-title":"Int J Biol Sci"},{"issue":"5","key":"2112_CR168","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1093\/nar\/gkad1193","volume":"52","author":"X Gu","year":"2024","unstructured":"Gu X, et al. Histone lactylation-boosted ALKBH3 potentiates tumor progression and diminished promyelocytic leukemia protein nuclear condensates by m1A demethylation of SP100A. Nucleic Acids Res. 2024;52(5):2273\u201389.","journal-title":"Nucleic Acids Res"},{"issue":"7","key":"2112_CR169","doi-asserted-by":"publisher","first-page":"8403","DOI":"10.1002\/cam4.5561","volume":"12","author":"M Xue","year":"2023","unstructured":"Xue M, et al. MFAP2, upregulated by m1A methylation, promotes colorectal cancer invasiveness via CLK3. Cancer Med. 2023;12(7):8403\u201314.","journal-title":"Cancer Med"},{"key":"2112_CR170","unstructured":"Liu L, et al. [Not Available]. Adv Sci (Weinh), 2024. 11(20): p. e2302379"},{"key":"2112_CR171","doi-asserted-by":"publisher","DOI":"10.1016\/j.redox.2023.102975","volume":"69","author":"SJ Chen","year":"2024","unstructured":"Chen SJ, et al. Epigenetically upregulated NSUN2 confers ferroptosis resistance in endometrial cancer via m(5)C modification of SLC7A11 mRNA. Redox Biol. 2024;69:102975.","journal-title":"Redox Biol"},{"issue":"15","key":"2112_CR172","doi-asserted-by":"publisher","first-page":"4254","DOI":"10.7150\/ijbs.60805","volume":"17","author":"J Cui","year":"2021","unstructured":"Cui J, et al. MicroRNA-196a promotes renal cancer cell migration and invasion by targeting BRAM1 to regulate SMAD and MAPK signaling pathways. Int J Biol Sci. 2021;17(15):4254\u201370.","journal-title":"Int J Biol Sci"},{"issue":"2","key":"2112_CR173","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1007\/s12272-021-01310-0","volume":"44","author":"M Xiang","year":"2021","unstructured":"Xiang M, et al. MiR-340 regulates the growth and metabolism of renal cell carcinoma cells by targeting frizzled class receptor 3. Arch Pharm Res. 2021;44(2):219\u201329.","journal-title":"Arch Pharm Res"},{"issue":"1","key":"2112_CR174","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1038\/s41419-020-03306-y","volume":"12","author":"Z Li","year":"2021","unstructured":"Li Z, et al. MicroRNA-153-5p promotes the proliferation and metastasis of renal cell carcinoma via direct targeting of AGO1. Cell Death Dis. 2021;12(1):33.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2112_CR175","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1159\/000526540","volume":"47","author":"Y Wu","year":"2022","unstructured":"Wu Y, Liao Q. MicroRNA-204-5p hampers the malignant progression of clear cell renal cell carcinoma through GXYLT2 downregulation. Kidney Blood Press Res. 2022;47(11):654\u201363.","journal-title":"Kidney Blood Press Res"},{"issue":"2","key":"2112_CR176","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41573-020-00091-3","volume":"20","author":"S Majumder","year":"2021","unstructured":"Majumder S, et al. Targeting notch in oncology: the path forward. Nat Rev Drug Discov. 2021;20(2):125\u201344.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"2112_CR177","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13046-023-02625-0","volume":"42","author":"S Liu","year":"2023","unstructured":"Liu S, et al. HES1-mediated down-regulation of miR-138 sustains NOTCH1 activation and promotes proliferation and invasion in renal cell carcinoma. J Exp Clin Cancer Res. 2023;42(1):72.","journal-title":"J Exp Clin Cancer Res"},{"key":"2112_CR178","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1016\/j.trsl.2022.06.009","volume":"249","author":"G Outeiro-Pinho","year":"2022","unstructured":"Outeiro-Pinho G, et al. Epigenetically-regulated miR-30a\/c-5p directly target TWF1 and hamper ccRCC cell aggressiveness. Transl Res. 2022;249:110\u201327.","journal-title":"Transl Res"},{"issue":"1","key":"2112_CR179","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12967-024-05988-w","volume":"23","author":"X Niu","year":"2025","unstructured":"Niu X, et al. miR-9-5p\/HMMR regulates the tumorigenesis and progression of clear cell renal cell carcinoma through EMT and JAK1\/STAT1 signaling pathway. J Transl Med. 2025;23(1):36.","journal-title":"J Transl Med"},{"issue":"5","key":"2112_CR180","doi-asserted-by":"publisher","first-page":"456","DOI":"10.1038\/s41419-022-04898-3","volume":"13","author":"Y Zhu","year":"2022","unstructured":"Zhu Y, et al. DMDRMR promotes angiogenesis via antagonizing DAB2IP in clear cell renal cell carcinoma. Cell Death Dis. 2022;13(5):456.","journal-title":"Cell Death Dis"},{"issue":"7","key":"2112_CR181","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41419-021-03955-7","volume":"12","author":"R Guo","year":"2021","unstructured":"Guo R, et al. LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p\/E2F2 axis in renal cell carcinoma. Cell Death Dis. 2021;12(7):689.","journal-title":"Cell Death Dis"},{"key":"2112_CR182","doi-asserted-by":"publisher","DOI":"10.1016\/j.canlet.2023.216463","volume":"578","author":"L Du","year":"2023","unstructured":"Du L, et al. LINC00926 promotes progression of renal cell carcinoma via regulating miR-30a-5p\/SOX4 axis and activating IFN\u03b3-JAK2-STAT1 pathway. Cancer Lett. 2023;578:216463.","journal-title":"Cancer Lett"},{"issue":"8","key":"2112_CR183","doi-asserted-by":"publisher","first-page":"3209","DOI":"10.7150\/ijbs.70289","volume":"18","author":"W Zhang","year":"2022","unstructured":"Zhang W, et al. Renal cell carcinoma-derived exosomes deliver lncARSR to induce macrophage polarization and promote tumor progression via STAT3 pathway. Int J Biol Sci. 2022;18(8):3209\u201322.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2112_CR184","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13046-023-02940-6","volume":"43","author":"H Xiao","year":"2024","unstructured":"Xiao H, et al. HIF-2\u03b1\/LINC02609\/APOL1-mediated lipid storage promotes endoplasmic reticulum homeostasis and regulates tumor progression in clear-cell renal cell carcinoma. J Exp Clin Cancer Res. 2024;43(1):29.","journal-title":"J Exp Clin Cancer Res"},{"issue":"7","key":"2112_CR185","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1038\/s41419-022-04996-2","volume":"13","author":"Y Liu","year":"2022","unstructured":"Liu Y, et al. Restoring the epigenetically silenced lncRNA COL18A1-AS1 represses ccRCC progression by lipid browning via miR-1286\/KLF12 axis. Cell Death Dis. 2022;13(7):578.","journal-title":"Cell Death Dis"},{"issue":"1","key":"2112_CR186","doi-asserted-by":"publisher","first-page":"260","DOI":"10.1186\/s13046-022-02452-9","volume":"41","author":"Y Wang","year":"2022","unstructured":"Wang Y, et al. LncRNA MILIP links YBX1 to translational activation of Snai1 and promotes metastasis in clear cell renal cell carcinoma. J Exp Clin Cancer Res. 2022;41(1):260.","journal-title":"J Exp Clin Cancer Res"},{"issue":"3","key":"2112_CR187","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1038\/s41388-019-0962-8","volume":"39","author":"H Shi","year":"2020","unstructured":"Shi H, et al. Targeting the TR4 nuclear receptor-mediated lncTASR\/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression. Oncogene. 2020;39(3):530\u201345.","journal-title":"Oncogene"},{"issue":"7","key":"2112_CR188","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/s41419-020-2713-8","volume":"11","author":"Y Liu","year":"2020","unstructured":"Liu Y, et al. Long noncoding RNA SNHG12 promotes tumour progression and sunitinib resistance by upregulating CDCA3 in renal cell carcinoma. Cell Death Dis. 2020;11(7):515.","journal-title":"Cell Death Dis"},{"issue":"2","key":"2112_CR189","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1038\/s41419-024-06510-2","volume":"15","author":"L Zhu","year":"2024","unstructured":"Zhu L, et al. Fumarate induces LncRNA-MIR4435-2HG to regulate glutamine metabolism remodeling and promote the development of FH-deficient renal cell carcinoma. Cell Death Dis. 2024;15(2):151.","journal-title":"Cell Death Dis"},{"issue":"37","key":"2112_CR190","doi-asserted-by":"publisher","first-page":"5639","DOI":"10.1038\/s41388-021-01971-7","volume":"40","author":"MX Zhang","year":"2021","unstructured":"Zhang MX, et al. Positive feedback regulation of lncRNA PVT1 and HIF2\u03b1 contributes to clear cell renal cell carcinoma tumorigenesis and metastasis. Oncogene. 2021;40(37):5639\u201350.","journal-title":"Oncogene"},{"issue":"1","key":"2112_CR191","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1158\/0008-5472.CAN-21-3432","volume":"83","author":"Y Pan","year":"2023","unstructured":"Pan Y, et al. Extracellular vesicle-mediated transfer of LncRNA IGFL2-AS1 confers Sunitinib resistance in renal cell carcinoma. Cancer Res. 2023;83(1):103\u201316.","journal-title":"Cancer Res"},{"issue":"6","key":"2112_CR192","doi-asserted-by":"publisher","first-page":"1500","DOI":"10.1158\/0008-5472.CAN-20-0832","volume":"81","author":"P Kulkarni","year":"2021","unstructured":"Kulkarni P, et al. A lncRNA TCL6-miR-155 interaction regulates the Src-Akt-EMT network to mediate kidney cancer progression and metastasis. Cancer Res. 2021;81(6):1500\u201312.","journal-title":"Cancer Res"},{"issue":"2","key":"2112_CR193","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1038\/s41419-021-03489-y","volume":"12","author":"X Xie","year":"2021","unstructured":"Xie X, et al. LncRNA CDKN2B-AS1 stabilized by IGF2BP3 drives the malignancy of renal clear cell carcinoma through epigenetically activating NUF2 transcription. Cell Death Dis. 2021;12(2):201.","journal-title":"Cell Death Dis"},{"issue":"4","key":"2112_CR194","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1158\/0008-5472.CAN-20-1619","volume":"81","author":"Y Gu","year":"2021","unstructured":"Gu Y, et al. DMDRMR-mediated regulation of m(6)A-modified CDK4 by m(6)A reader IGF2BP3 drives ccRCC progression. Cancer Res. 2021;81(4):923\u201334.","journal-title":"Cancer Res"},{"issue":"1","key":"2112_CR195","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s13045-021-01059-5","volume":"14","author":"L Yang","year":"2021","unstructured":"Yang L, et al. Low expression of TRAF3IP2-AS1 promotes progression of NONO-TFE3 translocation renal cell carcinoma by stimulating N(6)-methyladenosine of PARP1 mRNA and downregulating PTEN. J Hematol Oncol. 2021;14(1):46.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"2112_CR196","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1186\/s12943-022-01607-8","volume":"21","author":"Z Xu","year":"2022","unstructured":"Xu Z, et al. Circular RNA circPOLR2A promotes clear cell renal cell carcinoma progression by facilitating the UBE3C-induced ubiquitination of PEBP1 and, thereby, activating the ERK signaling pathway. Mol Cancer. 2022;21(1):146.","journal-title":"Mol Cancer"},{"issue":"1","key":"2112_CR197","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1186\/s12943-023-01912-w","volume":"23","author":"Z Zheng","year":"2024","unstructured":"Zheng Z, et al. CircPPAP2B controls metastasis of clear cell renal cell carcinoma via HNRNPC-dependent alternative splicing and targeting the miR-182-5p\/CYP1B1 axis. Mol Cancer. 2024;23(1):4.","journal-title":"Mol Cancer"},{"issue":"1","key":"2112_CR198","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12943-024-02122-8","volume":"24","author":"Y Wang","year":"2025","unstructured":"Wang Y, et al. circASAP1 induces renal clear cell carcinoma ferroptosis by binding to HNRNPC and thereby regulating GPX4. Mol Cancer. 2025;24(1):1.","journal-title":"Mol Cancer"},{"issue":"11","key":"2112_CR199","doi-asserted-by":"publisher","first-page":"4377","DOI":"10.1002\/jcb.29620","volume":"121","author":"L Lin","year":"2020","unstructured":"Lin L, Cai J. Circular RNA circ-EGLN3 promotes renal cell carcinoma proliferation and aggressiveness via miR-1299-mediated IRF7 activation. J Cell Biochem. 2020;121(11):4377\u201385.","journal-title":"J Cell Biochem"},{"issue":"7","key":"2112_CR200","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.994","volume":"12","author":"X Pan","year":"2022","unstructured":"Pan X, et al. Circular RNA circ-TNPO3 inhibits clear cell renal cell carcinoma metastasis by binding to IGF2BP2 and destabilizing SERPINH1 mRNA. Clin Transl Med. 2022;12(7):e994.","journal-title":"Clin Transl Med"},{"issue":"5","key":"2112_CR201","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/s41419-022-04863-0","volume":"13","author":"J Li","year":"2022","unstructured":"Li J, et al. Circular RNA circVAMP3 promotes aerobic glycolysis and proliferation by regulating LDHA in renal cell carcinoma. Cell Death Dis. 2022;13(5):443.","journal-title":"Cell Death Dis"},{"issue":"12","key":"2112_CR202","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1512","volume":"13","author":"Y Liu","year":"2023","unstructured":"Liu Y, et al. circRARS synergises with IGF2BP3 to regulate RNA methylation recognition to promote tumour progression in renal cell carcinoma. Clin Transl Med. 2023;13(12):e1512.","journal-title":"Clin Transl Med"},{"issue":"1","key":"2112_CR203","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1186\/s12943-021-01314-w","volume":"20","author":"J Cen","year":"2021","unstructured":"Cen J, et al. Circular RNA circSDHC serves as a sponge for miR-127-3p to promote the proliferation and metastasis of renal cell carcinoma via the CDKN3\/E2F1 axis. Mol Cancer. 2021;20(1):19.","journal-title":"Mol Cancer"},{"issue":"12","key":"2112_CR204","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1038\/s41419-022-05488-z","volume":"13","author":"B Zhao","year":"2022","unstructured":"Zhao B, et al. circPLIN2 promotes clear cell renal cell carcinoma progression by binding IGF2BP proteins and miR-199a-3p. Cell Death Dis. 2022;13(12):1030.","journal-title":"Cell Death Dis"},{"issue":"11","key":"2112_CR205","doi-asserted-by":"publisher","first-page":"2332","DOI":"10.1080\/15548627.2025.2503560","volume":"21","author":"M Zhou","year":"2025","unstructured":"Zhou M, et al. CircRNA GRAMD4 induces NBR1 expression to promote autophagy and immune escape in renal cell carcinoma. Autophagy. 2025;21(11):2332\u201352.","journal-title":"Autophagy"},{"issue":"6","key":"2112_CR206","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1038\/s12276-023-01010-3","volume":"55","author":"W Zhang","year":"2023","unstructured":"Zhang W, et al. piRNA-1742 promotes renal cell carcinoma malignancy by regulating USP8 stability through binding to hnRNPU and thereby inhibiting MUC12 ubiquitination. Exp Mol Med. 2023;55(6):1258\u201371.","journal-title":"Exp Mol Med"},{"issue":"10","key":"2112_CR207","doi-asserted-by":"publisher","first-page":"704","DOI":"10.1038\/nrg2634","volume":"10","author":"CM Croce","year":"2009","unstructured":"Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704\u201314.","journal-title":"Nat Rev Genet"},{"issue":"3","key":"2112_CR208","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1016\/j.cell.2018.01.011","volume":"172","author":"F Kopp","year":"2018","unstructured":"Kopp F, Mendell JT. Functional classification and experimental dissection of long noncoding RNAs. Cell. 2018;172(3):393\u2013407.","journal-title":"Cell"},{"issue":"8","key":"2112_CR209","doi-asserted-by":"publisher","DOI":"10.1002\/ctm2.1339","volume":"13","author":"J Cen","year":"2023","unstructured":"Cen J, et al. Hsa_circ_0057105 modulates a balance of epithelial-mesenchymal transition and ferroptosis vulnerability in renal cell carcinoma. Clin Transl Med. 2023;13(8):e1339.","journal-title":"Clin Transl Med"},{"issue":"1","key":"2112_CR210","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s12943-024-01940-0","volume":"23","author":"B Huang","year":"2024","unstructured":"Huang B, et al. A novel peptide PDHK1-241aa encoded by circPDHK1 promotes ccRCC progression via interacting with PPP1CA to inhibit AKT dephosphorylation and activate the AKT-mTOR signaling pathway. Mol Cancer. 2024;23(1):34.","journal-title":"Mol Cancer"},{"key":"2112_CR211","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202501211","author":"H Zhang","year":"2025","unstructured":"Zhang H, et al. CircPVT1 promotes lung metastasis and tumor progression in renal cell carcinoma by encoding the cP104aa peptide and targeting EIF4A3. Adv Sci (Weinh). 2025. https:\/\/doi.org\/10.1002\/advs.202501211.","journal-title":"Adv Sci (Weinh)"},{"issue":"30","key":"2112_CR212","doi-asserted-by":"publisher","DOI":"10.1002\/advs.202414398","volume":"12","author":"R Wang","year":"2025","unstructured":"Wang R, et al. piR-RCC suppresses renal cell carcinoma progression by facilitating YBX-1 cytoplasm localization. Adv Sci (Weinh). 2025;12(30):e14398.","journal-title":"Adv Sci (Weinh)"},{"issue":"1","key":"2112_CR213","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s12935-023-02978-8","volume":"23","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, et al. A three-snoRNA signature: SNORD15A, SNORD35B and SNORD60 as novel biomarker for renal cell carcinoma. Cancer Cell Int. 2023;23(1):136.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2112_CR214","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13062-024-00467-0","volume":"19","author":"K Gr\u00fctzmann","year":"2024","unstructured":"Gr\u00fctzmann K, et al. Identification of novel snoRNA-based biomarkers for clear cell renal cell carcinoma from urine-derived extracellular vesicles. Biol Direct. 2024;19(1):38.","journal-title":"Biol Direct"},{"issue":"1","key":"2112_CR215","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1186\/s13148-023-01471-3","volume":"15","author":"LY El Khoury","year":"2023","unstructured":"El Khoury LY, et al. Extensive intratumor regional epigenetic heterogeneity in clear cell renal cell carcinoma targets kidney enhancers and is associated with poor outcome. Clin Epigenetics. 2023;15(1):71.","journal-title":"Clin Epigenetics"},{"issue":"10","key":"2112_CR216","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.7150\/ijbs.83302","volume":"19","author":"Y Wang","year":"2023","unstructured":"Wang Y, et al. Loss of MIR503HG facilitates papillary renal cell carcinoma associated lymphatic metastasis by triggering NOTCH1\/VEGFC signaling. Int J Biol Sci. 2023;19(10):3266\u201384.","journal-title":"Int J Biol Sci"},{"issue":"4","key":"2112_CR217","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1016\/S1470-2045(18)30107-4","volume":"19","author":"TK Choueiri","year":"2018","unstructured":"Choueiri TK, et al. Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial. Lancet Oncol. 2018;19(4):451\u201360.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2112_CR218","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1056\/NEJMra1601333","volume":"376","author":"TK Choueiri","year":"2017","unstructured":"Choueiri TK, Motzer RJ. Systemic therapy for metastatic renal-cell carcinoma. N Engl J Med. 2017;376(4):354\u201366.","journal-title":"N Engl J Med"},{"key":"2112_CR219","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1225023","volume":"14","author":"L Yang","year":"2023","unstructured":"Yang L, et al. Prognostic and tumor microenvironmental feature of clear cell renal cell carcinoma revealed by m6A and lactylation modification-related genes. Front Immunol. 2023;14:1225023.","journal-title":"Front Immunol"},{"issue":"1","key":"2112_CR220","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1186\/s12943-024-02015-w","volume":"23","author":"K Zhuang","year":"2024","unstructured":"Zhuang K, et al. Assessment of SWI\/SNF chromatin remodeling complex related genes as potential biomarkers and therapeutic targets in pan-cancer. Mol Cancer. 2024;23(1):176.","journal-title":"Mol Cancer"},{"key":"2112_CR221","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.jare.2024.04.032","volume":"70","author":"Z Wei","year":"2025","unstructured":"Wei Z, et al. MIER2\/PGC1A elicits sunitinib resistance via lipid metabolism in renal cell carcinoma. J Adv Res. 2025;70:287\u2013305.","journal-title":"J Adv Res"},{"key":"2112_CR222","doi-asserted-by":"publisher","DOI":"10.3390\/ijms232416110","author":"A \u017dalimas","year":"2022","unstructured":"\u017dalimas A, et al. Urine molecular biomarkers for detection and follow-up of small renal masses. Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms232416110.","journal-title":"Int J Mol Sci"},{"issue":"28","key":"2112_CR223","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000029599","volume":"101","author":"A Koudonas","year":"2022","unstructured":"Koudonas A, et al. Methylation of PCDH17 and NEFH as prognostic biomarker for nonmetastatic RCC: A cohort study. Medicine (Baltimore). 2022;101(28):e29599.","journal-title":"Medicine (Baltimore)"},{"key":"2112_CR224","doi-asserted-by":"publisher","DOI":"10.3390\/ijms231911190","author":"J Serth","year":"2022","unstructured":"Serth J, et al. Identification of a novel renal metastasis associated CpG-Based DNA methylation signature (RMAMS). Int J Mol Sci. 2022. https:\/\/doi.org\/10.3390\/ijms231911190.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"2112_CR225","doi-asserted-by":"publisher","first-page":"14934","DOI":"10.1038\/s41598-021-94294-2","volume":"11","author":"K Gao","year":"2021","unstructured":"Gao K, et al. Expression patterns and prognostic value of RUNX genes in kidney cancer. Sci Rep. 2021;11(1):14934.","journal-title":"Sci Rep"},{"key":"2112_CR226","doi-asserted-by":"publisher","DOI":"10.1016\/j.cellsig.2023.110743","volume":"109","author":"Z Zeng","year":"2023","unstructured":"Zeng Z, et al. Downregulation of RAB17 have a poor prognosis in kidney renal clear cell carcinoma and its expression correlates with DNA methylation and immune infiltration. Cell Signal. 2023;109:110743.","journal-title":"Cell Signal"},{"issue":"1","key":"2112_CR227","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1186\/s12935-021-02047-y","volume":"21","author":"C Yang","year":"2021","unstructured":"Yang C, et al. LRRK2 is a candidate prognostic biomarker for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):343.","journal-title":"Cancer Cell Int"},{"issue":"1","key":"2112_CR228","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13148-023-01426-8","volume":"15","author":"X Wang","year":"2023","unstructured":"Wang X, et al. The prognostic value and immune correlation of IL18 expression and promoter methylation in renal cell carcinoma. Clin Epigenetics. 2023;15(1):14.","journal-title":"Clin Epigenetics"},{"issue":"1","key":"2112_CR229","doi-asserted-by":"publisher","first-page":"444","DOI":"10.1186\/s12885-021-08172-1","volume":"21","author":"O Katzendorn","year":"2021","unstructured":"Katzendorn O, et al. DNA methylation of tumor associated calcium signal transducer 2 (TACSTD2) loci shows association with clinically aggressive renal cell cancers. BMC Cancer. 2021;21(1):444.","journal-title":"BMC Cancer"},{"issue":"1","key":"2112_CR230","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13148-021-01084-8","volume":"13","author":"SC Joosten","year":"2021","unstructured":"Joosten SC, et al. Development of a prognostic risk model for clear cell renal cell carcinoma by systematic evaluation of DNA methylation markers. Clin Epigenetics. 2021;13(1):103.","journal-title":"Clin Epigenetics"},{"issue":"12","key":"2112_CR231","doi-asserted-by":"publisher","DOI":"10.1002\/jcla.24031","volume":"35","author":"X Jing","year":"2021","unstructured":"Jing X, et al. A five-gene methylation signature predicts overall survival of patients with clear cell renal cell carcinoma. J Clin Lab Anal. 2021;35(12):e24031.","journal-title":"J Clin Lab Anal"},{"issue":"38","key":"2112_CR232","doi-asserted-by":"publisher","first-page":"63703","DOI":"10.18632\/oncotarget.19476","volume":"8","author":"M Du","year":"2017","unstructured":"Du M, et al. Plasma exosomal miRNAs-based prognosis in metastatic kidney cancer. Oncotarget. 2017;8(38):63703\u201314.","journal-title":"Oncotarget"},{"issue":"11","key":"2112_CR233","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1245\/s10434-019-07578-3","volume":"26","author":"J Heinzelmann","year":"2019","unstructured":"Heinzelmann J, et al. 4-miRNA score predicts the individual metastatic risk of renal cell carcinoma patients. Ann Surg Oncol. 2019;26(11):3765\u201373.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2112_CR234","doi-asserted-by":"publisher","first-page":"10406","DOI":"10.1002\/jcb.27389","volume":"119","author":"C Ding","year":"2018","unstructured":"Ding C, et al. LncRNA CRNDE is a biomarker for clinical progression and poor prognosis in clear cell Renal Cell Carcinoma. J Cell Biochem. 2018;119(12):10406\u201314.","journal-title":"J Cell Biochem"},{"issue":"14","key":"2112_CR235","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.7150\/jca.40421","volume":"11","author":"H Liu","year":"2020","unstructured":"Liu H, et al. A panel of Four-lncRNA signature as a potential biomarker for predicting survival in clear Cell Renal Cell Carcinoma. J Cancer. 2020;11(14):4274\u201383.","journal-title":"J Cancer"},{"issue":"9","key":"2112_CR236","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.62347\/YCEB1273","volume":"15","author":"N Fujii","year":"2025","unstructured":"Fujii N, et al. Extracellular vesicle lncRNA AGAP2-AS1 as a non-invasive prognostic biomarker in patients with advanced Renal Cell Carcinoma. Am J Cancer Res. 2025;15(9):3919\u201332.","journal-title":"Am J Cancer Res"},{"issue":"1","key":"2112_CR237","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1186\/s12943-021-01443-2","volume":"20","author":"W Mao","year":"2021","unstructured":"Mao W, et al. ciRS-7 is a prognostic biomarker and potential gene therapy target for Renal Cell Carcinoma. Mol Cancer. 2021;20(1):142.","journal-title":"Mol Cancer"},{"issue":"17","key":"2112_CR238","doi-asserted-by":"publisher","first-page":"10177","DOI":"10.1111\/jcmm.15629","volume":"24","author":"R Yu","year":"2020","unstructured":"Yu R, Yao J, Ren Y. A novel circRNA, circNUP98, a potential biomarker, acted as an oncogene via the miR-567\/ PRDX3 axis in Renal Cell Carcinoma. J Cell Mol Med. 2020;24(17):10177\u201388.","journal-title":"J Cell Mol Med"},{"issue":"1","key":"2112_CR239","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12943-023-01824-9","volume":"22","author":"T He","year":"2023","unstructured":"He T, et al. Extracellular vesicle-circEHD2 promotes the progression of Renal Cell Carcinoma by activating cancer-associated fibroblasts. Mol Cancer. 2023;22(1):117.","journal-title":"Mol Cancer"},{"issue":"1","key":"2112_CR240","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13046-015-0180-3","volume":"34","author":"J Busch","year":"2015","unstructured":"Busch J, et al. Piwi-interacting RNAs as novel prognostic markers in clear cell Renal Cell Carcinomas. J Exp Clin Cancer Res. 2015;34(1):61.","journal-title":"J Exp Clin Cancer Res"},{"issue":"5","key":"2112_CR241","doi-asserted-by":"publisher","first-page":"4424","DOI":"10.18632\/aging.102894","volume":"12","author":"W Yang","year":"2020","unstructured":"Yang W, et al. Discovery and validation of the prognostic value of the lncRNAs encoding snoRNAs in patients with clear cell Renal Cell Carcinoma. Aging (Albany NY). 2020;12(5):4424\u201344.","journal-title":"Aging (Albany NY)"},{"issue":"1","key":"2112_CR242","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12935-020-01744-4","volume":"21","author":"X Shang","year":"2021","unstructured":"Shang X, et al. SNORD63 and SNORD96A as the non-invasive diagnostic biomarkers for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):56.","journal-title":"Cancer Cell Int"},{"issue":"3","key":"2112_CR243","doi-asserted-by":"publisher","first-page":"2215","DOI":"10.1111\/jcmm.14886","volume":"24","author":"Y Zhao","year":"2020","unstructured":"Zhao Y, et al. Expression signature of six-snoRNA serves as novel non-invasive biomarker for diagnosis and prognosis prediction of renal clear cell carcinoma. J Cell Mol Med. 2020;24(3):2215\u201328.","journal-title":"J Cell Mol Med"},{"key":"2112_CR244","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.3389\/fonc.2020.01566","volume":"10","author":"Z Mu","year":"2020","unstructured":"Mu Z, et al. Prognostic value of YTHDF2 in clear cell renal cell carcinoma. Front Oncol. 2020;10:1566.","journal-title":"Front Oncol"},{"issue":"7","key":"2112_CR245","doi-asserted-by":"publisher","first-page":"1041","DOI":"10.1038\/s41591-020-0933-1","volume":"26","author":"PV Nuzzo","year":"2020","unstructured":"Nuzzo PV, et al. Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes. Nat Med. 2020;26(7):1041\u20133.","journal-title":"Nat Med"},{"key":"2112_CR246","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1186\/s12916-014-0235-x","volume":"12","author":"BN Lasseigne","year":"2014","unstructured":"Lasseigne BN, et al. DNA methylation profiling reveals novel diagnostic biomarkers in renal cell carcinoma. BMC Med. 2014;12:235.","journal-title":"BMC Med"},{"key":"2112_CR247","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2024.102202","volume":"51","author":"Y Liu","year":"2025","unstructured":"Liu Y, et al. The 7-Methylguanosine (m7G) methylation METTL1 acts as a potential biomarker of clear cell renal cell carcinoma progression. Transl Oncol. 2025;51:102202.","journal-title":"Transl Oncol"},{"issue":"1","key":"2112_CR248","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12935-020-01738-2","volume":"21","author":"Y Wang","year":"2021","unstructured":"Wang Y, et al. Decreased expression of METTL14 predicts poor prognosis and construction of a prognostic signature for clear cell renal cell carcinoma. Cancer Cell Int. 2021;21(1):46.","journal-title":"Cancer Cell Int"},{"key":"2112_CR249","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.926461","volume":"13","author":"Z Jiang","year":"2022","unstructured":"Jiang Z, et al. A comprehensive investigation discovered the novel methyltransferase METTL24 as one presumably prognostic gene for kidney renal clear cell carcinoma potentially modulating tumor immune microenvironment. Front Immunol. 2022;13:926461.","journal-title":"Front Immunol"},{"key":"2112_CR250","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1186\/s12935-020-01238-3","volume":"20","author":"J Chen","year":"2020","unstructured":"Chen J, et al. Identification of a m(6)A RNA methylation regulators-based signature for predicting the prognosis of clear cell renal carcinoma. Cancer Cell Int. 2020;20:157.","journal-title":"Cancer Cell Int"},{"key":"2112_CR251","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.598017","volume":"11","author":"L Chen","year":"2021","unstructured":"Chen L, et al. m(6)A RNA methylation regulators impact prognosis and tumor microenvironment in renal papillary cell carcinoma. Front Oncol. 2021;11:598017.","journal-title":"Front Oncol"},{"key":"2112_CR252","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2022.832803","volume":"10","author":"L Zhang","year":"2022","unstructured":"Zhang L, et al. Identification of a Methylation-regulating genes prognostic signature to predict the prognosis and aid immunotherapy of clear cell renal cell carcinoma. Front Cell Dev Biol. 2022;10:832803.","journal-title":"Front Cell Dev Biol"},{"key":"2112_CR253","doi-asserted-by":"publisher","first-page":"6673","DOI":"10.2147\/CMAR.S323072","volume":"13","author":"H Li","year":"2021","unstructured":"Li H, et al. Prognostic value of an m(5)C RNA methylation regulator-related signature for clear cell renal cell carcinoma. Cancer Manag Res. 2021;13:6673\u201387.","journal-title":"Cancer Manag Res"},{"issue":"10","key":"2112_CR254","volume":"10","author":"F Hofmann","year":"2020","unstructured":"Hofmann F, et al. Targeted therapy for metastatic renal cell carcinoma. Cochrane Database Syst Rev. 2020;10(10):Cd012796.","journal-title":"Cochrane Database Syst Rev"},{"issue":"2","key":"2112_CR255","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s00262-024-03897-x","volume":"74","author":"G Roviello","year":"2025","unstructured":"Roviello G, et al. First-line immune-based combinations or sunitinib in favorable-risk metastatic renal cell carcinoma: a real-world retrospective comparison from the ARON-1 study. Cancer Immunol Immunother. 2025;74(2):65.","journal-title":"Cancer Immunol Immunother"},{"key":"2112_CR256","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2021.102295","volume":"100","author":"C Ciccarese","year":"2021","unstructured":"Ciccarese C, et al. Efficacy of VEGFR-TKIs plus immune checkpoint inhibitors in metastatic renal cell carcinoma patients with favorable IMDC prognosis. Cancer Treat Rev. 2021;100:102295.","journal-title":"Cancer Treat Rev"},{"key":"2112_CR257","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2021.111681","volume":"141","author":"\u00c2 Marques-Magalh\u00e3es","year":"2021","unstructured":"Marques-Magalh\u00e3es \u00c2, et al. Anti-neoplastic and demethylating activity of a newly synthetized flavanone-derived compound in renal cell carcinoma cell lines. Biomed Pharmacother. 2021;141:111681.","journal-title":"Biomed Pharmacother"},{"issue":"11","key":"2112_CR258","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2023.101287","volume":"4","author":"X Lu","year":"2023","unstructured":"Lu X, et al. Silencing of genes by promoter hypermethylation shapes tumor microenvironment and resistance to immunotherapy in clear-cell renal cell carcinomas. Cell Rep Med. 2023;4(11):101287.","journal-title":"Cell Rep Med"},{"issue":"22","key":"2112_CR259","doi-asserted-by":"publisher","first-page":"3813","DOI":"10.1158\/0008-5472.CAN-23-0401","volume":"83","author":"X Zhou","year":"2023","unstructured":"Zhou X, et al. SETD2 deficiency confers sensitivity to dual inhibition of DNA methylation and PARP in kidney cancer. Cancer Res. 2023;83(22):3813\u201326.","journal-title":"Cancer Res"},{"issue":"25","key":"2112_CR260","doi-asserted-by":"publisher","first-page":"11444","DOI":"10.7150\/thno.48469","volume":"10","author":"Z Xiong","year":"2020","unstructured":"Xiong Z, et al. Restoring the epigenetically silenced PCK2 suppresses renal cell carcinoma progression and increases sensitivity to sunitinib by promoting endoplasmic reticulum stress. Theranostics. 2020;10(25):11444\u201361.","journal-title":"Theranostics"},{"issue":"3","key":"2112_CR261","doi-asserted-by":"publisher","first-page":"995","DOI":"10.7150\/ijbs.67329","volume":"18","author":"D Peng","year":"2022","unstructured":"Peng D, et al. Ascorbic acid induced TET2 enzyme activation enhances cancer immunotherapy efficacy in renal cell carcinoma. Int J Biol Sci. 2022;18(3):995\u20131007.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"2112_CR262","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1038\/s41420-024-02187-w","volume":"10","author":"Q Luo","year":"2024","unstructured":"Luo Q, et al. N6-methyladenosine-modified TRIM37 augments sunitinib resistance by promoting the ubiquitin-degradation of SmARCC2 and activating the Wnt signaling pathway in renal cell carcinoma. Cell Death Discov. 2024;10(1):418.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2112_CR263","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1038\/s41420-023-01423-z","volume":"9","author":"B Cheng","year":"2023","unstructured":"Cheng B, et al. Vascular mimicry induced by m(6)A mediated IGFL2-AS1\/AR axis contributes to pazopanib resistance in clear cell renal cell carcinoma. Cell Death Discov. 2023;9(1):121.","journal-title":"Cell Death Discov"},{"issue":"1","key":"2112_CR264","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s12964-022-00831-5","volume":"20","author":"Z Liu","year":"2022","unstructured":"Liu Z, et al. METTL14-mediated N(6)-methyladenosine modification of ITGB4 mRNA inhibits metastasis of clear cell renal cell carcinoma. Cell Commun Signal. 2022;20(1):36.","journal-title":"Cell Commun Signal"},{"issue":"1","key":"2112_CR265","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1038\/s41416-022-01757-y","volume":"127","author":"L Zhang","year":"2022","unstructured":"Zhang L, Luo X, Qiao S. METTL14-mediated N6-methyladenosine modification of Pten mRNA inhibits tumour progression in clear-cell renal cell carcinoma. Br J Cancer. 2022;127(1):30\u201342.","journal-title":"Br J Cancer"},{"key":"2112_CR266","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.omtn.2021.12.024","volume":"27","author":"D Shen","year":"2022","unstructured":"Shen D, et al. METTL14-mediated Lnc-LSG1 m6A modification inhibits clear cell renal cell carcinoma metastasis via regulating ESRP2 ubiquitination. Mol Ther Nucleic Acids. 2022;27:547\u201361.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"2","key":"2112_CR267","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1111\/cas.15212","volume":"113","author":"T Liu","year":"2022","unstructured":"Liu T, et al. Methyltransferase-like 14 suppresses growth and metastasis of renal cell carcinoma by decreasing long noncoding RNA NEAT1. Cancer Sci. 2022;113(2):446\u201358.","journal-title":"Cancer Sci"},{"issue":"1","key":"2112_CR268","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1186\/s12943-022-01549-1","volume":"21","author":"Y Chen","year":"2022","unstructured":"Chen Y, et al. N(6)-methyladenosine-modified TRAF1 promotes sunitinib resistance by regulating apoptosis and angiogenesis in a METTL14-dependent manner in renal cell carcinoma. Mol Cancer. 2022;21(1):111.","journal-title":"Mol Cancer"},{"issue":"1","key":"2112_CR269","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1080\/13880209.2020.1738503","volume":"58","author":"L Dai","year":"2020","unstructured":"Dai L, et al. Resveratrol inhibits ACHN cells via regulation of histone acetylation. Pharm Biol. 2020;58(1):231\u20138.","journal-title":"Pharm Biol"},{"issue":"18","key":"2112_CR270","doi-asserted-by":"publisher","first-page":"895","DOI":"10.2217\/epi-2023-0150","volume":"15","author":"Z Chen","year":"2023","unstructured":"Chen Z, et al. Resveratrol affects ccRCC cell senescence and macrophage polarization by regulating the stability of CCNB1 by RBM15. Epigenomics. 2023;15(18):895\u2013910.","journal-title":"Epigenomics"},{"issue":"11","key":"2112_CR271","doi-asserted-by":"publisher","first-page":"11776","DOI":"10.1096\/fj.201802614RRR","volume":"33","author":"T Zhang","year":"2019","unstructured":"Zhang T, et al. Erianin alleviates diabetic retinopathy by reducing retinal inflammation initiated by microglial cells via inhibiting hyperglycemia-mediated ERK1\/2-NF-\u03baB signaling pathway. FASEB J. 2019;33(11):11776\u201390.","journal-title":"FASEB J"},{"issue":"3","key":"2112_CR272","doi-asserted-by":"publisher","first-page":"367","DOI":"10.7150\/jca.81027","volume":"14","author":"H Shen","year":"2023","unstructured":"Shen H, et al. Erianin induces ferroptosis of renal cancer stem cells via promoting ALOX12\/P53 mRNA N6-methyladenosine modification. J Cancer. 2023;14(3):367\u201378.","journal-title":"J Cancer"},{"issue":"5","key":"2112_CR273","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/s41401-022-01022-1","volume":"44","author":"SJ Yang","year":"2023","unstructured":"Yang SJ, et al. Ginsenoside Rg1 in neurological diseases: from bench to bedside. Acta Pharmacol Sin. 2023;44(5):913\u201330.","journal-title":"Acta Pharmacol Sin"},{"issue":"7","key":"2112_CR274","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1007\/s00204-018-2229-5","volume":"92","author":"N Kiweler","year":"2018","unstructured":"Kiweler N, et al. The histone deacetylases HDAC1 and HDAC2 are required for the growth and survival of renal carcinoma cells. Arch Toxicol. 2018;92(7):2227\u201343.","journal-title":"Arch Toxicol"},{"issue":"5","key":"2112_CR275","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1007\/s10637-019-00880-7","volume":"38","author":"AM Molina","year":"2020","unstructured":"Molina AM, et al. NCI 6896: a phase I trial of vorinostat (SAHA) and isotretinoin (13-cis retinoic acid) in the treatment of patients with advanced renal cell carcinoma. Invest New Drugs. 2020;38(5):1383\u20139.","journal-title":"Invest New Drugs"},{"issue":"4","key":"2112_CR276","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1038\/s41591-024-02813-1","volume":"30","author":"F Wang","year":"2024","unstructured":"Wang F, et al. Combined anti-PD-1, HDAC inhibitor and anti-VEGF for MSS\/pMMR colorectal cancer: a randomized phase 2 trial. Nat Med. 2024;30(4):1035\u201343.","journal-title":"Nat Med"},{"key":"2112_CR277","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyaf155","author":"L Wang","year":"2025","unstructured":"Wang L, et al. First-line treatment with HDACis plus tislelizumab combined with chemotherapy in advanced NSCLC: a single-arm phase II study. Oncologist. 2025. https:\/\/doi.org\/10.1093\/oncolo\/oyaf155.","journal-title":"Oncologist"},{"issue":"1","key":"2112_CR278","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1158\/1078-0432.CCR-18-1589","volume":"25","author":"AC Ferrari","year":"2019","unstructured":"Ferrari AC, et al. Epigenetic therapy with Panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin Cancer Res. 2019;25(1):52\u201363.","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2112_CR279","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1158\/1078-0432.CCR-22-2168","volume":"29","author":"JA Ligon","year":"2023","unstructured":"Ligon JA, et al. A phase II trial of Guadecitabine in children and adults with SDH-deficient GIST, pheochromocytoma, paraganglioma, and HLRCC-associated renal cell carcinoma. Clin Cancer Res. 2023;29(2):341\u20138.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"2112_CR280","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2023.112016","volume":"42","author":"HT Li","year":"2023","unstructured":"Li HT, et al. RNA mis-splicing drives viral mimicry response after DNMTi therapy in SETD2-mutant kidney cancer. Cell Rep. 2023;42(1):112016.","journal-title":"Cell Rep"},{"key":"2112_CR281","doi-asserted-by":"publisher","DOI":"10.3390\/cancers16234058","author":"T Narukawa","year":"2024","unstructured":"Narukawa T, et al. The novel HDAC inhibitor OBP-801 promotes MHC class I presentation through LMP2 upregulation, enhancing the PD-1-targeting therapy in clear cell renal cell carcinoma. Cancers (Basel). 2024. https:\/\/doi.org\/10.3390\/cancers16234058.","journal-title":"Cancers (Basel)"},{"key":"2112_CR282","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00328","volume":"8","author":"ES Tsang","year":"2024","unstructured":"Tsang ES, et al. Updated survival follow-up for phase ib trial of the histone deacetylase inhibitor abexinostat with pazopanib in patients with solid tumor malignancies. JCO Precis Oncol. 2024;8:e2400328.","journal-title":"JCO Precis Oncol"}],"container-title":["Clinical Epigenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13148-026-02112-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02112-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13148-026-02112-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T02:03:01Z","timestamp":1779847381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13148-026-02112-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,4]]},"references-count":282,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2112"],"URL":"https:\/\/doi.org\/10.1186\/s13148-026-02112-1","relation":{},"ISSN":["1868-7083"],"issn-type":[{"value":"1868-7083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,4]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare that they have no competing of interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing of interests"}}],"article-number":"99"}}